We are developing a minimally invasive, mechanical blood circulatory device, known as a ventricular assist device (LVAD) for heart failure (HF) patients. By disrupting the current LVAD paradigm, we aspire to significantly reduce heart failure treatment costs while dramatically improving clinical outcomes as well as the quality and length of life for patients. Our CEO, Dr. Sudhir Kushwaha is a thought leader in this space, as the Medical Director of the Cardiac Transplant and Mechanical Circulatory Support Program at the Mayo Clinic. The Company was born from Sudhir’s experience in managing his team that perform heart transplants and provide circulatory therapy to patients including LVAD implantation. He took a radically different approach in LVAD design in an effort to eliminate the shortcomings of the currently available LVADs, which now share a US$1 billion and growing market. Our principal design goals were to achieve: (i) minimally invasive, reversible implantation; (our pump is placed in the aorta above the aortic valve); (ii) full synchronized pulsatility to minimize known clinical adverse side effects and supplement natural heart function (pump failure need not result in mortality); (iii) efficacy as an LVAD, RVAD or BiVAD solution; and (iv) a fully implanted system, without external wires, charged through the skin. We have completed the prototype development of our MI-VADTM device, which has undergone preliminary “proof of concept” testing in a live animal model. We have acquired issued patents in the US, Europe and China and have other patent filings worldwide in progress, which will secure maximum protection for our inventions. We are continuing the development of our device through technical refinement and system integration, together with additional animal studies leading to a design freeze in preparation for preliminary human implantation. We have assembled a world-class team of medical and engineering professionals to join us on this exciting journey.